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A B S T R A C T
Introduction: Light transmission aggregometry (LTA) is the gold standard for diagnosing bleeding disorders.
Although LTA is laborious, requires large volumes of blood and is relatively insensitive to small changes in
platelet function, there is still no competing alternative approach to replace LTA for the diagnosis of platelet
bleeding disorders.
Materials and methods: This study investigates the correlation between flow cytometry-based whole blood pla-
telet activation test (WB-PACT) and LTA and whether WB-PACT is of additional value for the identification of
bleeding disorders. In total, 161 patients with suspected bleeding diathesis were tested.
Results: A correlation of 0.41 between LTA and WB-PACT was found, and there was agreement between tests in
62% of cases (κ = 0.23). The WB-PACT is of additional value to LTA to detect platelet function disorders (PFD)
as 10 patients with elevated bleeding score (BS) were detected with WB-PACT, 4 with LTA and 7 patients were
positive with both tests. Interestingly, in contrast to LTA, WB-PACT has an additional option to detect VWF
disfunctions.
Conclusion: WB-PACT may have added value for the routine diagnostic work-up in patients who need to have
platelet function tested.
1. Introduction
The assessment of platelet (dys)function is required for the identi-
fication of mild bleeding disorders (MBDs) characterized by dis-
proportional bleeding after trauma or surgery, menorrhagia, excessive
and frequent mucocutaneous hemorrhage and easy bruising [1,2].
Currently, light transmission aggregometry (LTA) is the ‘gold stan-
dard’ platelet function test to define suspected bleeding disorders.
Although LTA is used for more than four decades in diagnostic la-
boratories, it still lacks sensitivity for mild platelet function defects
(PFDs) and it does not predict the risk of bleeding complications among
patients with various platelet function defects [3–8]. It has been shown
that only 60% of patients with excessive clinical bleeding and a sus-
pected underlying inherited PFD, had a demonstrable abnormality in
platelet aggregation [9], while in patients with mild bleeding, ap-
proximately 40% had a defect when assessed by LTA and serotonin and
ATP release measurements [9,10]. Disadvantages of LTA are the poor
standardization despite existing guidelines, the requirement of a con-
siderable volume of a fresh blood sample and the fact that it is time and
labor intensive and not applicable for samples with low platelet count
[11–16]. Accordingly, alternative methods to measure platelet ag-
gregation have been developed but despite potential advantages, none
of these techniques competed with LTA with regard to bleeding diag-
nostics [16]. There is an urgent need for alternative methods to give
complimentary information about mild platelet function defects.
The whole blood platelet activation test (WB-PACT), introduced in
1987 by Shattil et al. [17], is a flow cytometric approach that allows
stimulation of platelets with multiple agonists, while platelet activation
can be quantified with different types of activation markers of granule
release, glycoprotein activation and phospholipid expression. Since
many laboratories do not offer facilities for both aggregometry and flow
cytometry, data regarding the agreement between both approaches are
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Fig. 1. The WB-PACT was scored by first determining the 2.5th, 10th and 25th percentiles for WB-PACT parameters in 56 healthy donors. In patients, if MFI was
lower than the 2.5th percentile (0–2.5%), between the 2.5th and 10th percentiles (2.5–10%), between the 10th and 25th percentiles (10–25%) or higher than the
25th percentile (> 25%) a score of 3, 2, 1 or 0 was given, respectively (panel A). For LTA, maximal aggregation, disaggregation and prolongation of the lagtime were
scored. In patients, if maximum aggregation was between 0% and 25%, between 25% and 50%, between 50% and 75% or more than 75% as score of 3, 2, 1, 0 was
given, respectively. If disaggregation was present, a score of 2 or 1 was given depending on the agonist and if an increase in lagtime was measured a score of 1 was
given (panel B). Patients with at least one parameter lower than the 10th percentile measured with WB-PACT and at least one value deviating from the normal range
measured with LTA were categorized as abnormal for PFD.
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scarce and these data would be of great value to correctly interpret the
results achieved with either of these two approaches. For the diagnosis
of MBDs, recently, Boknäs et al. [18] suggested that flow cytometric
analysis of platelet function could become a feasible alternative for
LTA, while van Asten et al. [19] concluded that this approach has added
value to LTA.
In this study, we compared LTA and WB-PACT for the detection of
PFDs in patients with bleeding diathesis.
2. Materials and methods
2.1. Study population
Platelet function by LTA and WB-PACT was measured in parallel in
161 patients investigated for bleeding diathesis and in 56 healthy
controls. We expected a 20% lower expression in patients with bleeding
diathesis. Based on an alpha of 0.05 and a 1-beta of 0.8, we calculated
that 46 subjects per group are sufficient to find significant differences
between patients and controls. We used the following website for the
power calculations: https://www.stat.ubc.ca/~rollin/stats/ssize/n2.
html. For the patients investigated for bleeding diathesis, a bleeding
score was calculated using the ISTH-BAT (elevated BS:> 5 in
women,> 3 in men and>2 in children) [27]. Our study protocol was
approved by the ethical committee of the Ghent University Hospital.
Citrated whole blood (BD Vacutainer, Becton Dickinson, Plymouth, UK)
was collected and processed according to the recommendations for the
standardization of LTA [16].
2.2. Reagents
Platelet agonists used for flow cytometric analysis of platelet func-
tion include the P2Y12 agonists 2MeS-ADP (1624, Tocris), the protease
activated receptor (PAR)-1 agonist thrombin receptor activator peptide
(TRAP-6 (SFLLRN), H-2936; Bachem, Germany), the glycoprotein VI
(GPVI) agonist collagen-related peptide (CRP, purchased from Professor
Farndale, University of Cambridge, UK) [28]. Ristocetin was purchased
from ABP Ltd. (Germany). The monoclonal antibodies used were FITC-
conjugated PAC1, directed against the activated αIIbβ3 receptor, PE-
conjugated anti-P-selectin (CD62P, clone AK4), APC-conjugated anti-
GPIb (CD42b, clone HIP1) and APC-conjugated anti-αIIbβ3 (CD41a), all
purchased from BD Pharmingen (NJ, USA) and FITC-conjugated anti-
VWF (CL7616F, Cedarlane, Burlington, USA).
Platelet agonists, used for LTA were ADP, epinephrine, arachidonic
acid, ristocetin (Avant- Medical, The Netherlands), U46619 (Sigma
Aldrich, Belgium) and collagen (Takeda Pharma, Austria).
2.3. Whole blood platelet activation test (WB-PACT)
Platelet activation tests for flow cytometric analysis were prepared
as published earlier [29,30]. In short, test strips consisting of no ago-
nist, 30 μmol/l TRAP, 5 μg/ml CRP and 2 μmol/l MeSADP were pre-
pared in advance and stored at −20 °C. Each reaction mixture with a
total volume of 20 μl consists of 2 μl FITC-conjugated PAC-1, 1.5 μl PE-
conjugated anti-P-selectin and 0.5 μl APC-conjugated anti-CD42b with
or without agonist in HEPES-buffered saline (HBS, 10mmol/l HEPES,
150mmol/l NaCl, 1 mmol/l MgSO4, 5mmol/l KCL, pH 7.4). In addi-
tion, test strips were prepared with no agonist, 1.2 mg/ml or 0.2mg/ml
ristocetin in a reaction mixture of 2 μl FITC-conjugated anti-VWF and
0.5 μl APC-conjugated anti-CD41a in HEPES buffered saline, and stored
at −20 °C.
Whole blood was kept at RT for at least 30min and maximum 4 h.
Test strips were thawed to 37 °C and shortly centrifuged. Subsequently,
whole blood was incubated at 37 °C for 10min and diluted 1:4 in pre-
heated HEPES-buffered saline to minimize the formation of platelet
aggregates. From this diluted blood, 5 μl was added to each reaction
mixture (20 μl, final dilution 1:20) and the tests were incubated for
exactly 20min at 37 °C. Reactions were stopped by adding 250 μl
fixation solution (137mmol/l NaCl, 2.7 mmol/l KCl, 1.12mmol/l
NaH2PO4, 1.15mmol/l KH2PO4, 10.2 mmol/l Na2HPO4, 4mmol/l
EDTA, 0.5% formaldehyde).
A FACS Canto™ II (BD Biosciences, Erembodegem, Belgium) was
used to analyze the samples (Supplemental Fig. 1). First, using the
forward and sideward scatter pattern and gating on the CD42b or
CD41a positive cells, platelets were discriminated from other cells.
Fluorescent intensity in the FITC gate and PE gate was selected to de-
termine activated αIIbβ3 or VWF binding and P-selectin density, re-
spectively and results are expressed as median fluorescent intensity
(MFI) minus the MFI of the unstimulated cells. Single measurements
were performed as intra-assay precision for this assay is below 5% with
the exception of P-selectin expression in response to MesADP (below
10%) [29].
2.3.1. Light transmission aggregometry
Light transmission aggregometry (LTA) was performed on a chrono-
log model 700 (Chrono-log corporation, Havertown, US) according to
the manufacturer's instructions and to the North American Consensus
Guideline on platelet function testing [15]. Platelet-rich citrate plasma
was obtained after centrifugation (10min, 180g/min) (Hettich Uni-
versal 32; DJB Labcare, Buckinghamshire, UK). LTA curves were as-
sessed after addition of 25 μl of the agonists ADP (2.5 and 5 μmol/l),
collagen (2.5 and 5 μg/ml), ristocetin (0.5 and 1.5 mg/ml), epinephrine
(10 μmol/l), arachidonic acid (AA) (1mmol/l), and thromboxane A2
analogue (1 μmol/l) to 225 μl platelet rich citrate plasma. Light trans-
mission was recorded for 6min and compared to platelet poor plasma
(PPP). Aggregation was expressed as % maximum aggregation com-
pared to PPP, lagtime was expressed in seconds. Disaggregation was
defined as the difference between maximal and final platelet aggrega-
tion after 6min expressed as percentage and> 20% of disaggregation
was considered significant. For LTA imprecision is below 8% for all
parameters, ristocetin low concentration not considered because of the
low maximal aggregation as expected in normal individuals. In routine
setting, single measurements are performed, and abnormal results are
repeated as confirmation for decreased maximal aggregation or dis-
aggregation.
2.4. VWF antigen and VWF activity
The HemosIL AcuStar VWF:Ag assay (VWF:Ag Acustar) and
HemosIL AcuStar VWF:RCo assay (Instrumentation Laboratory) was
performed on an ACL AcuStar™ (Instrumentation Laboratory) using
magnetic particles coated with anti-VWF polyclonal antibodies (antigen
detection) or Recombinant GPIbα (rGPIbα) (activity measurement)




All Men Women Children
1. Patients with bleeding
diathesis
N 161 31 100 30
Age, years; median (IQR) 32 (20–51) 54 (27–61) 35.5
(24–50)
9 (4–13)
VWF:Ag (%); median (IQR) 93 (68–122)
VWF:Rco; median (IQR) 87 (64–120)
BS
N of BS reported 117 22 72 23
median BS 3 2 3 2
% of elevated BS 25 32 18 39
N, number of patients; IQR, interquartile ranges; BS, bleeding score; N of BS
reported, number of patients interviewed to determine a bleeding score.
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Fig. 2. Both αIIbβ3 receptor activation (left panels) and P-selectin expression (right panels) in response to MeSADP (A), CRP (B) and TRAP (C) was determined in
blood of patients with bleeding diathesis. In addition, VWF binding was determined in response to 1.5 mg/ml ristocetin (D) in the same population. The 50th
(median), 25th, 10th and 2.5th percentiles, of the healthy population are indicated. If patients are between the 25th and 10th percentile (green), they received a score
of one point for each agonist. If patients are between the 10th and 2.5th percentile (blue), they received a score of two points for each agonist. If patients are below
the 2.5th percentile (red), they received a score of three points for each agonist.
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2.5. Scoring system platelet function tests
The WB-PACT by flow cytometry quantifies αIIbβ3 activation and P-
selectin expression in response to MeSADP, TRAP and CRP. Similarly,
this test can be used to quantify VWF binding to platelets in response to
ristocetin. The 2.5th, 10th and 25th percentiles for WB-PACT para-
meters were determined in 56 healthy donors to score the patients
samples and the scoring system is shown in Fig. 1A. For LTA, maximal
aggregation, disaggregation and prolongation of the lagtime in response
to ADP, collagen, epinephrine, AA, a thromboxane A2 analogue and
ristocetin was scored (Fig. 1B).
To study the agreement between both tests in patients investigated
for bleeding diathesis, patients with at least one parameter lower than
the 10th percentile measured with WB-PACT or at least one parameter
deviating from the normal range measured with LTA (< 50% maximal
aggregation, prolonged lagtime and/or disaggregation>20%) were
categorized as abnormal for PFD.
2.6. Statistics
Analyses were performed using the software packages SPSS version
23.0 and GraphPad Prism 6. Spearman rank correlations were used to
test for correlations between the different methods. Agreement between
the methods was assessed using two-by-two analysis and Cohen's kappa
statistic. P-values< 0.05 were considered statistically significant.
3. Results
Patient characteristics, bleeding assessment and platelet function.
In total, 161 patients with a bleeding diathesis (median age
32 years) were included in the study (Table 1). A bleeding score was
reported for 117 of 161 patients and an elevated BS was reported for
32%, 18% and 39% of men, women and children, respectively.
Platelet function was measured in response to MeSADP, CRP, TRAP
and ristocetin and the extent of αIIbβ3 activation, P-selectin expression
and VWF binding to platelets is shown in Fig. 2. In addition, platelet
aggregation with LTA was measured according to general clinical
practice [15]. For each agonist, a score was calculated for both WB-
PACT and LTA (Fig. 1). For WB-PACT the median score (minimum-
maximum) in patients with expected bleeding diathesis was 1 (0–6), 0
(0–6), 1 (0–6) and 0 (0–3) for MeSADP, CRP, TRAP and ristocetin, re-
spectively. For LTA the median score (minimum-maximum) was 1
(0−10), 0 (0–5), 0 (0–4), 0 (0–5), 0 (0–4) and 0 (0–1) in response to
ADP, collagen, epinephrine, TXA2 analogue, arachidonic acid and ris-
tocetin, respectively. The distribution of the scores in the patients with
bleeding diathesis is shown in Supplemental Fig. 2. The inter-individual
variation was between 23% and 53% when platelets were activated
with TRAP or CRP and 52% and 140% when stimulated with MesADP
for P-selectin expression and αIIbβ3 activation, respectively.
More in detail, the binding of VWF to platelets detected by flow
cytometry was more sensitive for diagnosing deviations in VWF con-
centration or function than ristocetin induced platelet agglutination
measured with LTA (Fig. 3). In total, 29 patients were detected with
abnormal VWF:Ag and/or VWF:RCo, and interestingly, 21/29 patients
had an increased score for ristocetin (high concentration) induced
binding of VWF to platelets (WB-PACT). More in detail, 8/29 patients
were abnormal for VWF-binding to platelets (score > 1 i.e.< 10th
percentile). In contrast, for LTA, only 1 out of 29 patients had a score
different from zero (score 1 i.e.< 75% agglutination) for ristocetin
induced agglutination of platelets.
3.1. Correlation and agreement between LTA and WB-PACT
Furthermore, a Spearman correlation coefficient of 0.41 between
LTA platelet activation score versus WB-PACT platelet activation score
was observed (Fig. 4). Furthermore, for 99 of 161 patients (62%) there
was agreement between the tests (κ =0.23, P= .003) with 46 patients
(29%) diagnosed with PFDs and 53 patients (33%) without PFD. In
total, 25 (15%) and 37 (23%) patients were diagnosed with PFD ac-
cording to LTA and WB-PACT, respectively.
In the group that was diagnosed with PFDs by both LTA and WB-
PACT, 25% of the patients had an elevated bleeding score (Fig. 5A). For
patients with PFDs according to WB-PACT only and LTA only, an ele-
vated BS was recorded for 33% and 21% of the patients, respectively
(Fig. 5B and C). In total, 8 (6 women and 2 men) out of 29 patients
(28%) with an elevated BS were not diagnosed with PACT nor LTA
(Supplemental Fig. 3). In the group of children with elevated BS, 7 out
of 9 children were detected with WB-PACT (78%), while only 4 out of 9
children were detected with LTA (44%). However, when combining
both tests, all children with elevated BS were detected. Remarkably, in
the group patients with a normal BS, 24% were diagnosed with PFD
with both tests, 17% with LTA, 23% with WB-PACT, and 36% of
Fig. 3. The scoring of the conventional methods to investigate VWF con-
centration and function was based on low VWF:Ag and/or low VWF:RCo (score
1) and normal VWF:Ag and VWF:RCo (score 0). The binding of VWF to platelets
(WB-PACT) and platelet agglutination (LTA) in response to low and high con-
centrations of ristocetin is scored according to Fig. 1.
Fig. 4. Correlation of WB-PACT with LTA for determining platelet function in
patients suspected for bleeding diathesis. The Spearman correlation coefficient
and P value are depicted.
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patients were found negative for PFDs (Supplemental Fig. 3B).
4. Discussion
This study investigates the (additional) value of flow cytometric
analysis of platelet function in patients with suspected thrombocyto-
pathy.
For the WB-PACT, the inter-individual variation in patients with
suspected thrombocytopathy was high with %CV up to 55% (apart from
P-selectin expression in response to MeSADP). This is higher compared
to a healthy population (N=129) where the inter-individual variation
was around 30% (apart from P-selectin expression in response to ADP)
[29]. The higher variation can be explained by the presence of platelet
defects in some patients while others have a normal platelet response.
As expected, we observed a weak correlation between the total
scores of all parameters/agonists of LTA and WB-PACT in the study
population. It was in line with our expectations that there was no
complete correlation, because there are major differences between LTA
(a semi-quantitative method) and whole blood PACT (a quantitative
analysis) [33]. Our findings and findings of others [19] show that LTA
and WB-PACT are complimentary tests, which give supplemental in-
sights in the bleeding risk, indicating that the tests improve each other's
prediction.
Our data seem to demonstrate that LTA is insensitive to detect de-
viations in VWF concentration or function by measuring platelet ag-
glutination induced by high concentrations of ristocetin as none of the
patients had an abnormal response (score > 1). Indeed, LTA is mostly
used to detect gain-of-function defects VWD (type2B, platelet type) by
low ristocetin induced agglutination [8]. Interestingly, WB-PACT was
able to detect a reduced binding of VWF in response to ristocetin in a
population of patients with suspected thrombocytopathy, and data
corresponded well with decreased VWF:Ag and/or VWF:RCo. Other
differences between the LTA and the WB-PACT include different ago-
nists that were used. Unlike LTA, the WB-PACT does not contain a
thromboxane analogue, AA or epinephrine, however, it does include a
PAR-1 activating peptide. In the past we validated U46619 and epi-
nephrine with WB-PACT, however both agonists gave too much
variation between measurements. The triple helical cross-linked CRP is
a powerful GPVI agonist, however, CRP is sensitive to GPVI density on
the platelet surface. Furthermore, despite an essential role of GPVI in
the formation of a stable platelet thrombus, no overt bleeding pheno-
type was observed either in GPVI deficient mice or in patients with a
congenital GPVI deficiency [34,35]. Although GPVI plays a crucial role
in collagen-dependent thrombus formation, it shows a low affinity for
collagen and the adhesion of platelets on collagen is considerably en-
hanced by interaction with integrin α2β1 [36,37]. Together, in re-
sponse to collagen, α2β1 and GPVI synergistically stimulate Ca2+ sig-
naling, and platelet aggregation [36,38]. Furthermore, a limitation of
this study is the determination of the cut-off values for WB-PACT. The
reference population only consisted of 56 healthy individuals instead of
the 120 recommended by the CSLI guidelines and the 10th percentile
was used as the cut-off value. Also, the score model was not previously
validated in a group of severe defined PFD. However, in a previous
study, we showed that the PACT assay discriminates Bernard-Soulier
from non-Bernard-Soulier by the absence of binding of the anti-GPIb
antibody, while Glanzmann thrombasthenia is discriminated from non-
Glanzmann thrombasthenia by the absence of αIIbβ3 antibody binding
to platelets [19].
In patients presenting with suspicion of bleeding diathesis, we show
a weak agreement between the two tests (concordant in 62% of the
cases, κ=0.23). In other studies, this agreement was higher (con-
cordant in 65% of the cases, κ=0.32), which may be explained by the
different agonist panels and the different patient populations (exclusion
of children, pregnancy, von Willebrand disease and factor deficiency)
[19]. In patient populations with a history of excessive bleeding
(median BS=13), the agreement between the tests is much higher
(concordant in 84% of cases, κ=0.67) [39] then in populations with
milder bleeding phenotypes.
The unified ISTH-BAT, has gained general acceptance, and the
uniform reporting of reference ranges according to age and gender al-
lows standardization of the results and comparison between studies
[27,40]. We observed that 28% of patients with elevated BS were not
diagnosed with WB-PACT nor LTA and that 64% of patients with
normal BS were detected with PFD according to LTA and/or WB-PACT.
Fig. 5. Agreement of bleeding score (BS) with PFD according to both LTA and WB-PACT (panel A), to only WB-PACT (panel B) and to only LTA (panel C).
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This is in contrast with the high negative predictive value of the ISTH-
BAT reported earlier [41,42]. However, a systemic review does not
support this finding and report that, as disease prevalence in the studies
was low (because most patients do not have a MBD) there are many
true-negative test results, but the lower sensitivity in these studies in-
dicates that the few patients with a MBD still could be missed by the
ISTH-BAT [43].
In conclusion, in this population consisting of patients suspected for
thrombocytopathy, a weak correlation was found between WB-PACT
test results and the results from the widely used LTA test. Although 28%
of patients with high BS were not detected with WB-PACT nor LTA, all
children with elevated BS had either a positive LTA or a positive WB
PACT test. A major advantage of WB-PACT is that the ristocetin induced
VWF-binding to platelets can be measured in exactly the same setting as
platelet activation. Ristocetin induced VWF-binding to platelets is a
representative measurement for VWF:Ag and VWF:RCo positivity.
Therefore, based on the present results in combination with the ad-
vantages compared to LTA (little amount of blood needed, less pre-
processing steps and quantitative results), WB-PACT may have added
value for the routine diagnostic work-up in patients who need to have
platelet function tested.
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